-
Corxel Pharmaceuticals Secures Global Rights to CX11, a Novel Oral GLP-1 RA, in Licensing Deal with Vincentage
•
China-based Corxel Pharmaceuticals (CORXEL) has announced a significant licensing agreement with domestic firm Vincentage, securing global development and commercialization rights to CX11 (also known as VCT220), an oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), excluding Greater China. The financial details of the agreement have not been disclosed. CX11:…
-
ETERN Therapeutics’ YAP/TEAD Inhibitor ETS-006 Wins FDA Clinical Approval for Advanced Solid Tumors
•
China-based biopharmaceutical company ETERN Therapeutics has announced that it has received clinical approval from the US Food and Drug Administration (FDA) for its YAP/TEAD inhibitor, ETS-006, which targets multiple advanced solid tumors. ETS-006: A Promising Oral YAP/TEAD PPI InhibitorETS-006 is an oral YAP/TEAD protein-protein interaction (PPI) inhibitor that has shown…
-
Bristol-Myers Squibb’s Opdivo-Yervoy Combo Approved by EC for MSI-H/mCRC
•
Global biopharmaceutical company Bristol-Myers Squibb (BMS, NYSE: BMY) has announced that it has received marketing approval from the European Commission (EC) for its combination therapy of Opdivo (nivolumab) and Yervoy (ipilimumab). This treatment is indicated for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient…
-
Roche’s Lunsumio Receives NMPA Approval for R/R Follicular Lymphoma Treatment
•
Swiss pharmaceutical giant Roche (SWX: ROG) has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its bispecific antibody (BsAb), Lunsumio (mosunetuzumab). This therapy targets CD20 and CD3 and is designed to treat adult patients with recurrent or refractory follicular lymphoma (R/R FL) who…
-
BeiGene Rebrands to BeOne Medicines Ltd, Ticker Symbol Changes to “ONC”
•
China-based BeiGene Ltd, listed on Nasdaq (NASDAQ: BGNE, HKG: 6160, SHA: 688235), has announced a significant brand transformation, changing its Nasdaq ticker symbol to “ONC” effective January 2, 2025. This move is accompanied by a proposed English name change to BeOne Medicines Ltd, highlighting the company’s dedication to delivering innovative…
-
RAPT Therapeutics Secures Ex-China Rights to Jemincare Group’s Anti-IgE Antibody JYB1904
•
US-based biopharmaceutical company RAPT Therapeutics Inc. (NASDAQ: RAPT) has announced that it has obtained the ex-Greater China rights to Jiangxi Jemincare Group’s long-acting anti-IgE antibody, JYB1904, through a significant licensing agreement. The deal involves an upfront payment of USD 35 million and potential milestone payments of up to USD 672.5…
-
Porton Pharma and Dragon Sail Join Forces to Enhance ADC Drug Development
•
China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions has entered into a strategic partnership with fellow Chinese firm Dragon Sail Pharmaceutical (Shanghai) Co., Ltd. This collaboration aims to focus on the research and development (R&D), manufacturing, and supply chain of antibody drug conjugates (ADCs), with no financial terms…
-
GSK’s Jemperli Combo Shows Improved PFS in Phase III Ovarian Cancer Trial
•
UK-based GSK plc (NYSE: GSK) has announced a positive readout from the Phase III FIRST-ENGOT-OV44 trial for Jemperli (dostarlimab), a programmed death-1 (PD-1) inhibitor, when combined with Zejula (niraparib) for the first-line treatment of advanced ovarian cancer. The trial evaluated the addition of Jemperli to the standard of care carboplatin-paclitaxel…
-
Pfizer’s Braftovi Receives FDA Approval for Metastatic Colorectal Cancer Treatment
•
US-based Pfizer (NYSE: PFE) has announced receiving an indication extension approval from the US Food and Drug Administration (U.S. FDA) for Braftovi (encorafenib) in combination with cetuximab and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. Braftovi’s Existing…
-
Eli Lilly’s Zepbound Receives FDA Approval for Moderate-to-Severe OSA and Obesity
•
US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has revealed that the US Food and Drug Administration (FDA) has granted another indication approval for its drug Zepbound (tirzepatide), marking it as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. Zepbound can…
-
Novo Nordisk’s Alhemo Receives FDA Approval for Hemophilia A and B Prophylaxis
•
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced that the US Food and Drug Administration (FDA) has granted marketing approval for its Alhemo (concizumab-mtci) injection. The drug is indicated as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years…
-
Boehringer Ingelheim-SEC Joint Incubator Launches in Shenzhen’s Luohu District
•
On December 23, the Boehringer Ingelheim-SEC Joint innovative incubator was inaugurated in Luohu District, Shenzhen. This marks the establishment of the first high-specification innovation platform in the Guangdong-Hong Kong-Macau Greater Bay Area (GBA), co-hosted by a multinational pharmaceutical company and an innovation center. State-of-the-Art Facilities and Support for Biopharmaceutical EntrepreneursThe…
-
CStone Pharmaceuticals Initiates First-in-Human Trial for PD-1/VEGF/CTLA-4 Trispecific Antibody CS2009
•
China-based CStone Pharmaceuticals (HKG: 2616) has announced the clinical filing for its CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, in Australia. This first-in-human study is registered and published on Clinicaltrials.gov with the NCT number: NCT06741644. Innovative Design and Mechanism of CS2009CS2009 boasts an innovative molecular design that simultaneously targets PD-1, VEGFA, and…
-
Becton, Dickinson and Co. Launches RMB1.332 Billion Factory in Jiangsu for Pre-Filled Syringes
•
US-based Becton, Dickinson and Co., (BD) has officially put into operation its new factory in Yixing, Jiangsu province, with an investment worth RMB1.332 billion (USD182.5 million). This plant marks BD’s third world-class local production base in China and is now the central facility for local manufacturing of BD pre-filled flush…
-
C.Q. Pharmaceutical Holding to Come Under SASAC’s Indirect Control via Genertec Acquisition
•
C.Q. Pharmaceutical Holding Co., Ltd (SHE: 000950), a Chongqing-based pharmaceutical company, is set to be indirectly controlled by China’s State-owned Assets Supervision and Administration Commission of the State Council (SASAC). The company has entered into an acquisition agreement with China General Technology (Group) Holding Co Ltd (Genertec), a centrally administered…
-
Yifan Pharmaceutical’s Evive Biotech Receives ANVISA Approval for Ryzneuta
•
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary, Evive Biotech Ltd, has received marketing approval from the Brazil National Health Surveillance Agency (ANVISA) for Ryzneuta (efbemalenograstim alfa, F-627). This approval follows previous marketing nods in China, the United States, and the European Union. Ryzneuta (F-627): A…
-
Changchun BCHT Biotechnology Receives NMPA Approval for HSV-2 mRNA Vaccine LVRNA101
•
Changchun BCHT Biotechnology Co., Ltd (SHA: 688276), a China-based biotechnology company, has announced receiving clinical trial approval from the National Medical Products Administration (NMPA) for its mRNA vaccine, LVRNA101. The vaccine is designed to prevent genital herpes caused by herpes simplex virus type 2 (HSV-2) infection. HSV-2 and the Need…
-
Shenzhen Chipscreen Biosciences Gets NMPA Approval for CS231295 Solid Tumor Study
•
Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a China-based biopharmaceutical company, has announced receiving the go-ahead from the National Medical Products Administration (NMPA) to conduct a clinical study for its drug candidate CS231295 in advanced solid tumors. CS231295: A Promising Multi-Target InhibitorCS231295 is a multi-target protein kinase inhibitor that has…
-
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval to Test SHR-1681 in Clinical Trials
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with clinical testing of its Category 1 biologic product, SHR-1681. Novel Biologic Product SHR-1681The product, SHR-1681, is designed to specifically bind to antigens present on the surface…
-
CSPC Pharmaceutical’s SYH9017 Receives NMPA Clearance for Weight Management Clinical Trial
•
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced clinical clearance from the National Medical Products Administration (NMPA) for its SYH9017, a biosimilar version of Denmark-based Novo Nordisk’s (NYSE: NVO) weight loss drug semaglutide (Ozempic/Wegovy). The clearance allows SYH9017 to proceed to clinical trials focused on weight management for…
